Title

The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis.

Permalink

https://escholarship.org/uc/item/0kf9q0zb

Journal

The Lancet Diabetes & Endocrinology, 11(10)

Authors

Xu, Yanning
Derakhshan, Arash
Hysaj, Ola
et al.

Publication Date

2023-10-01

DOI

10.1016/S2213-8587(23)00227-9

Peer reviewed

The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis

Yanning Xu, MD[1,2], Arash Derakhshan, MD[1,2], Ola Hysaj, MSc[3], Lea Wildisen, PhD[3], Till Ittermann, PhD[4,5], Alessandro Pingitore, MD[6], Nazanin Abolhassani, PhD[3], Marco Medici, MD[1,7], Prof Lambertus A L M Kiemeney, PhD[8], Prof Niels P Riksen, MD[7], Robin P F Dullaart, MD[9], Stella Trompet, PhD[10], Prof Marcus Dörr, MD[5,11], Suzanne J Brown, BSc[12], Prof Börge Schmidt, PhD[13], Prof Dagmar Führer-Sakel, MD[14], Mark P J Vanderpump, MD[15], Axel Muendlein, PhD[16], Prof Heinz Drexel, MD[16,17,18], Prof Howard A Fink, MD[19,20], Prof M Kamran Ikram, MD[2,21], Maryam Kavousi, MD[2], Connie M Rhee, MD[22], Prof Isabela M Bensenor, MD[23], Prof Fereidoun Azizi, MD[24], Prof Graeme J Hankey, MD[25,26], Prof Massimo Iacoviello, MD[27], Misa Imaizumi, PhD[28], Prof Graziano Ceresini, MD[29], Luigi Ferrucci, PhD[30], José A Sgarbi, MD[31], Prof Douglas C Bauer, MD[32], Prof Nick Wareham, MD[33], Prof Kristien Boelaert, MD[34], Prof Stephan J L Bakker, MD[9], Prof J Wouter Jukema, MD[35,36], Bert Vaes, MD[37], Prof Giorgio Iervasi, MD[6], Prof Bu B Yeap, PhD[25,38], Prof Rudi G J Westendorp, MD[39], Tim I M Korevaar, MD[1], Prof Henry Völzke, MD[4,5], Salman Razvi, MD[40], Prof Jacobijn Gussekloo, MD[41], Prof John P Walsh, PhD[12,25], Prof Anne R Cappola, MD[42], Prof Nicolas Rodondi, MD[3,43], Prof Robin P Peeters, MD[1], Layal Chaker, MD[1,2],
Thyroid Studies Collaboration

Correspondence to: Layal Chaker, Address: Department of Internal Medicine, Department of Epidemiology, Academic Center for Thyroid Diseases, Erasmus University Medical Center, PO Box 2040, 3000CA Rotterdam, The Netherlands. l.chaker@erasmusmc.nl, Phone: +31 0107036551.

Contributors: LC and RPP designed the study. YX, AD, LC, TIMK, RPP participated in the systematic review of literature and study selection. YX and LC had full access to anonymized individual-participant data. YX and LC performed analyses and were involved in the writing of the first draft of the manuscript. All other authors were involved in data collection and substantially contributed to drafting of the work with critical revision for important intellectual content. LC and RPP supervised analyses, were involved in writing of the manuscript, and directed the project. All authors read and approved the final manuscript. YX, LC and RPP had the final responsibility for the decision to submit for publication. The corresponding author (LC) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Data sharing: Our data protection agreements with the TSC and participating cohorts do not allow us to share individual-level data from these cohorts to third parties.

[1]Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands

[2]Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands

[3]Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

[4]Institute for Community Medicine, Clinical-Epidemiological Research, University Medicine Greifswald, Germany

[5]German Center for Cardiovascular Research (DZHK), Partner site Greifswald, Germany

[6]National Research Council (CNR) Institute of Clinical Physiology, Pisa, Italy

[7]Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands

[8]Radboud University Medical Center, Radboud Institute for Health Sciences, Department for Health Evidence, Nijmegen, the Netherlands

[9]Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

[10]Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, the Netherlands

[11]Department of Internal Medicine B, University Medicine Greifswald, Germany

[12]Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia

[13]Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Germany

[14]Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

[15]The Physicians' Clinic, London, England, UK

[16]Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria

[17]Private University of the Principality of Liechtenstein, Triesen, Liechtenstein

[18]Drexel University College of Medicine, Philadelphia, PA, USA

[19]Geriatric Research Education and Clinical Center, VA Healthcare System, Minneapolis, Minnesota, USA

[20]Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA

[21]Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands

[22]Harold Simmons Center for Chronic Disease Research and Epidemiology, University of California Irvine School of Medicine, Orange, California, USA

[23]Department of Internal Medicine, University of São Paulo Medical School, São Paulo, Brazil

[24]Endocrine Research Center and Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

[25]The University of Western Australia, Perth, Australia

[26]Perron Institute for Neurological and Translational Science, Nedlands, Western Australia

[27]Cardiology Unit, Cardiothoracic Department, University Polyclinic Hospital of Bari, Bari, Italy

[28]Department of Clinical Studies, Radiation Effects Research Foundation, Nagasaki, Japan

[29]Department of Medicine and Surgery, Unit of Internal Medicine and Onco-Endocrinology, University Hospital of Parma, Parma, Italy

[30]Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA

[31]Division of Endocrinology and Metabolism, Faculdade de Medicina de Marília, Marília, Brazil

[32]Departments of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, USA

[33]Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK

[34]Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

[35]Dept. of Cardiology, Leiden University Medical Center, Leiden, the Netherlands

[36]Netherlands Heart Institute, Utrecht, the Netherlands

[37]Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium

[38]Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Australia

[39]Department of Public Health and Center of Healthy Aging, University of Copenhagen, Copenhagen, Denmark

[40]Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

[41]Department of Public Health and Primary Care and Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands

[42]Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

[43]Department of General Internal Medicine, Inselspital, University of Bern, Switzerland

Summary

Background—Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are statistically defined by the $2 \cdot 5^{th}$–$97 \cdot 5^{th}$ percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT4 based on the risk of cardiovascular disease (CVD) and mortality.

Methods—This systematic review and individual participant data (IPD) meta-analysis identified eligible prospective cohorts through the Thyroid Studies Collaboration, supplemented with a

systematic search via Embase, MEDLINE (Ovid), Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from January 2011 to October 2022. We included cohorts that collected TSH and/or FT4, cardiovascular outcomes and/or mortality for adults. The primary outcome was a composite outcome including CVD events (coronary heart disease, stroke, and heart failure) and all-cause mortality. Secondary outcomes included CVD events, all-cause mortality, and CVD mortality. We performed one-step (cohort-stratified Cox models) and two-step (random-effects models) meta-analyses adjusting for age, sex, smoking, systolic blood pressure, diabetes mellitus, and total cholesterol. The study protocol was registered with PROSPERO CRD42017057576.

Findings—We identified 3935 studies, of which 53 cohorts fulfilled the inclusion criteria and 26 cohorts agreed to participate. We included IPD on 134 346 participants with a median age of 59 years. There was a J-shaped association of FT4 with the composite outcome and secondary outcomes, with the 20th- 40th percentiles of FT4 (median 13·5–14·8 pmol/L) conveying the lowest risk. Compared to the 20th- 40th percentiles, the age- and sex-adjusted HR (95% CI) for FT4 in the 80th-100th percentiles was 1·20 (1·11–1·31) for the composite outcome, 1·34 (1·20–1·49) for all-cause mortality, 1·57 (1·31–1·89) for CVD mortality and 1·22 (1·11–1·33) for CVD events. In individuals aged 70 years, ten-year absolute risk of composite outcome increased over 5% for women with FT4 >85th percentile (median 17·6 pmol/L), and men with FT4 >75th percentile (16·7 pmol/L). Nonlinear associations were identified for TSH, with the 60th-80th percentiles of TSH (median 1·90–2·90 mIU/L) associated with the lowest risk of CVD and mortality. Compared to the 60th –80th percentiles, the age- and sex-adjusted HR (95% CI) of TSH in the 0th-20th percentiles was 1·07 (1·02–1·12) for the composite outcome, 1·09 (1·05 to 1·14) for all-cause mortality, and 1·07 (0·99–1·16) for CVD mortality.

Interpretation—There was a J-shaped association of FT4 with CVD and mortality. Low concentrations of TSH were associated with a higher risk of all-cause mortality and CVD mortality. The 20th-40th percentiles of FT4 and the 60th-80th percentiles of TSH could represent the optimal healthy ranges of thyroid function based on the risk of CVD and mortality, with more than 5% increase of ten-year composite risk identified for FT4 >85th percentile in women and men aged over 70 years. We propose a feasible approach to establish the optimal healthy ranges of thyroid function, allowing for better identification of individuals with a higher risk of thyroid-related outcomes.

Funding—None

Introduction

Reference ranges are used to interpret the results of biomarkers and assist clinical decision making. There are usually two ways to determine reference ranges.[1] One way is to define the reference intervals by the 2·5th to 97·5th percentiles according to the distribution in the apparently healthy population. This has been applied to many biomarkers used in the clinic, including thyroid-stimulating hormone (TSH) and free thyroxine (FT4). However, these reference intervals do not account for the risk of adverse clinical outcomes. Several studies have shown that differences of thyroid function within the reference intervals are related to an increased risk of atrial fibrillation,[2] stroke,[3] heart failure, and mortality.[4] Therefore,

current reference intervals may fail to identify individuals with a higher risk of disease who could potentially benefit from intervention.

Another approach to define reference ranges is to establish clinical decision limits, based on outcomes from clinical studies. Results from clinical studies rather than statistically defined reference intervals are increasingly used to optimize clinical-decision making.[1] For example, the upper limit of BMI is defined by the risk of mortality and related diseases,[5] which would be much higher if defined by the 97·5th percentile, considering the high prevalence of obesity worldwide. Another example is that more stringent treatment thresholds for low-density lipoprotein cholesterol have been applied to patients with a high risk of cardiovascular disease due to the benefits shown by intensive lipid-lowering therapy in randomized controlled trials (RCTs).[6] Clinical decision limits are usually based on thresholds applied in RCTs, indicating the benefits from interventions. However, there is a lack of long-term RCTs to determine the clinical decision limits for thyroid function. Alternatively, results from large observational studies can provide practical evidence. Most guidelines of subclinical hypothyroidism (elevated TSH combination with FT4 within the reference range) recommend treatment when TSH >10 mIU/L,[7,8] given the increased risk of cardiovascular disease (CVD)[9,10] as well as progression to overt hypothyroidism.[11] However, TSH concentrations lower than currently used treatment thresholds are already associated with a higher risk of fatal coronary heart disease (CHD).[9] Moreover, FT4 has been implicated in stronger associations with clinical parameters compared to TSH.[12] Higher FT4 concentrations with TSH within the reference range may be associated with increased all-cause mortality, particularly in older age.[13,14] Applying an epidemiological approach, we could assess the risk of adverse clinical consequences analysing TSH and FT4 as continuous variables. Thus, the optimal healthy ranges for TSH and FT4 would be defined as being associated with the lowest risk. Although thyroid hormones have pleiotropic effects, the cardiovascular system is one of the most studied and important targets. Exploring the optimal healthy ranges of thyroid function based on the risk of CVD and mortality could be seen as a proof of concept before extending to other clinical outcomes and establishing the proper clinical decision limits. This has already been undertaken within the Rotterdam Study, but those analyses only focused on CVD events in a single population.[15] Optimal healthy ranges can be particularly relevant for thyroid function, with levothyroxine as one of the most commonly prescribed drugs worldwide and an estimated 7% of the U.S. population having an active prescription.[16]

We aimed to evaluate the association between thyroid function (i.e., TSH and FT4 concentrations) and the composite risk of CVD and mortality with individual-participant data (IPD) meta-analyses, and to further identify the age- and sex-specific optimal healthy ranges according to the risk estimates.

Methods

Search strategy and selection criteria

This IPD meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participant Data. According to our registered protocol on PROSPERO (CRD42017057576), we identified studies mainly through the Thyroid Studies

Collaboration (TSC),[9] a consortium of cohorts recruited through a systematic search (from 1950 through 2010). We additionally conducted a systematic literature search of the Embase, MEDLINE (Ovid), Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from January 1st, 2011 through February 12th, 2017 with no language restrictions to identify potentially eligible cohorts. We further updated the systematic search to October 13th, 2022 to gain insight into which cohorts we have potentially missed. The search strategies used are described in appendix pp 4–5. We included prospective population-based cohorts with TSH and/or FT4 measured in adults as well as CVD events and/or mortality recorded. We excluded cohorts that included solely 1) pregnant women, 2) individuals with overt thyroid diseases, and 3) individuals with CVD. Eligibility for inclusion was assessed by four reviewers (AD, YX, LC, TIMK) independently with any disagreement resolved by a fifth independent reviewer (RPP). We assessed study quality and risk of bias with the Newcastle-Ottawa Scale.[17]

Data analysis

We invited all eligible cohorts to collaborate and provide IPD on demographics, TSH, FT4, thyroid peroxidase antibodies (TPOAb), history of CVD and risk factors (smoking, diabetes mellitus, systolic blood pressure, total cholesterol, and anthropometrics), medication use mostly defined by the Anatomical Therapeutic Chemical (ATC) codes (thyroid-altering medication including amiodarone, antithyroid drugs, thyroid hormone replacement, glucocorticoids, iodine; lipid-lowering and antihypertensive medication), CVD events, CVD mortality, and all-cause mortality. We confirmed that participants characteristics and results obtained from each cohort were consistent with previous publications. If any discrepancies were found, we contacted the primary study investigators to clarify and solve any differences. Each cohort was approved by local ethics committees and had obtained informed consent from participants. Formal ethical approval for this project was exempted by the medical ethics committee of Erasmus University Medical Center Rotterdam (MEC-2022-0237, 16-05-2022).

The primary outcome was a composite outcome, defined as the first occurrence of CVD events (CHD, stroke, and heart failure) or all-cause mortality following study entry. CVD events, CVD mortality, and all-cause mortality were assessed separately as secondary outcomes. In the primary analysis of the composite outcome, only cohorts providing all the elements of the composite outcome were included. However, we deployed a sensitivity analysis to include all cohorts with available information on CHD events and all-cause mortality, since they are the main components of the composite outcome. Detailed definitions of CVD events and CVD mortality are provided in appendix pp 8-10.

A detailed description of statistical analyses is provided in the appendix pp 5–7. In brief, TSH and FT4 concentrations were transformed into cohort-specific percentiles to harmonize the data ascertained through different assays between the cohorts. We performed a one-step IPD meta-analysis as our main analysis, applying cohort-stratified Cox proportional hazards models with different baseline hazard functions for each cohort.[18] Given the prior knowledge that both insufficient and excess circulating thyroid hormones are deleterious to the cardiovascular system, potential nonlinear association was expected and was assessed

with restricted cubic splines with three knots at the 10th, 50th, and 90th percentiles. The percentiles of TSH and FT4 with the lowest hazard ratio of outcomes were recorded and used as reference values to depict the associations.

As a validation, we additionally conducted a two-step IPD meta-analysis, pooling estimates from the individual cohorts with a random-effects model (DerSimonian and Laird[19]). Based on the percentiles with the lowest risk (the 60th-80th percentiles of TSH, the 20th-40th percentiles of FT4) identified in one-step meta-analyses, we categorized TSH and FT4 into quintiles and selected the fourth quintile of TSH and the second quintile of FT4 as the reference groups. The I-square statistic[20] was used to assess the heterogeneity across cohorts and publication bias was evaluated by funnel plots and Egger's test.[21]

All the analyses were adjusted for age and sex in the first model. We additionally adjusted for other traditional cardiovascular risk factors, including smoking, systolic blood pressure, diabetes mellitus, and total cholesterol in the second model,[9] also took the availability of data in most cohorts into account. We conducted the multi-level multiple imputation for missing covariates value (0%–100%) in the second model with five imputed datasets in both one-step and two-step meta-analyses.[22,23] Exact number and the proportion of missing covariates for each cohort is shown in appendix pp 11–12. Given potential mediation effects of most covariates, data imputation and reduced sample size in the second model, the results of the first model are presented as the main results.

To explore the source of heterogeneity and identify potential effect modification, we extended the one-step meta-analyses with interaction terms and conducted prespecified subgroup analyses. Subgroup analyses were performed on age (<70 and 70 years[24]; 18–49 years, 50–69 years, 70–79 years, and 80 years), sex, race (White, non-White), and iodine status (as defined by Iodine Global Network[25] using data that was the closest to the entry time and information provided by cohorts). We calculated ten-year absolute risk estimates with stratification by both age and sex to further quantify the effect estimates (i.e., hazard ratios [HRs]).

We conducted several sensitivity analyses to test the robustness of our results, including additional adjustments for antihypertensives, lipid-lowering medication and body mass index, restricting analyses to euthyroid participants (either defined by reference intervals used by each cohort according to the assay or the 2·5th-97·5th percentiles of each cohort), using log-transformed TSH and FT4 or standardized TSH and FT4, using repeated measurements of thyroid function, excluding participants with thyroid-altering medication or positive TPOAb, excluding cohorts not using a third generation assay, excluding participants with history of CVD and/or diabetes, including only studies with formal adjudication procedures for CVD outcomes and including cohorts with available data on CHD events and mortality in the analysis of composite outcome (i.e., less well defined composite outcome). All the analyses were done using SPSS (version 26) and R statistical software (version 4·1·0, packages rms, smoothHR, micemd, meta, forestplot).

Results

We identified 3935 studies after removing duplicates, of which 3783 were excluded based on the review of titles and abstracts and 99 after the full-text screening, resulting in 53 potentially eligible cohorts. With more than two-year of efforts, 26 prospective cohorts with sufficient data agreed to participate in this IPD meta-analysis (figure 1). Further update of the systematic search identified six additional cohorts. The included cohorts were from Europe (n=15), Brazil (n=2), USA (n=5), Japan (n=1), Australia (n=2), and Iran (n=1), which provided data on 134 346 participants with TSH available (103 407 participants with FT4 available) with a median (IQR) follow-up of 11·5 (7·7–14·9) years. The entry year of included cohorts ranged from 1974 to 2012. The median age of participants from each cohort ranged from 38 to 85 years, with an overall median age of 59 (range 18–106) years at baseline (table 1 and appendix pp 11–12). The corresponding values of percentiles of TSH and FT4 were provided in appendix pp 13–15. The composite outcome was available in thirteen cohorts, with 18 173 (30·3%) events among 59 907 participants. All cohorts provided information on all-cause mortality (32 943 [24·5%] events in 134 344 persons), and twenty-four cohorts also reported CVD mortality (10 076 [8·2%] events in 122 939 persons). Thirteen cohorts reported CVD events (12 212 [20·4%] events in 59 907 persons), and eight of them used formal adjudication procedures.

We plotted HRs generated from the one-step meta-analyses using the FT4 percentile with the lowest HR as a reference. There was a consistent J-shaped association between FT4 and the composite outcome as well as secondary outcomes. Overall, FT4 between the 20th (median value of the 20th percentile in all cohorts 13·5 [IQR 11·2–13·9] pmol/L) and 40th percentiles (median 14·8 [12·3–15·0] pmol/L) conferred the minimum risk of the composite outcome, all-cause mortality, CVD mortality, and CVD events. Above the 50th percentile of FT4 (median 15·3 [12·7–15·8] pmol/L), the risk of each outcome increased with increasing FT4 in a largely linear manner (figure 2). Further adjustment with covariates in the second model did not change the results significantly (appendix p 18).

In concordance with one-step meta-analyses, a J-shaped trend of FT4 was identified across the quintiles in two-step analyses. Compared to the 20th-40th percentiles, the age- and sex-adjusted HR of FT4 in the 80th-100th percentiles was 1·20 (95% CI 1·11–1·31) for the composite outcome, 1·34 (1·20–1·49) for all-cause mortality, 1·57 (1·31–1·89) for CVD mortality and 1·22 (1·11–1·33) for CVD events (figure 3a). The effect sizes attenuated slightly after additional adjustment with the second model (appendix p 19). I^2 values ranged from 0% to 82%. No relevant publication bias was identified by funnel plots or Egger's tests (appendix pp 38–41).

Significant interaction terms between age and FT4 were identified for the composite outcome, CVD mortality, and CVD events (p for interaction=0·0034, 0·025, 0·011 respectively). A nonlinear association of FT4 with the composite outcome and secondary outcomes was identified for all age-stratified analyses (appendix p 20). Compared with younger participants, the concentration of FT4 conveying the lowest risk was slightly lower for participants aged   70 years. The increased risk of composite outcome and CVD events with increasing FT4 was more prominent among individuals   70 years. Stratified analyses

with more age groups also demonstrated a more pronounced effect of FT4 as age increased over the age of 50. A U-shaped association was identified for individuals aged 18–49 years (figure 4). The risk of composite outcome and all-cause mortality was differential between men and women (p for interaction 0·10, 0·042 respectively), with lower concentrations of FT4 associated with the lowest risk among women (appendix p 21). Among individuals 70 years, the ten-year absolute risk estimate increased more than 5% for women with FT4 above the 85th percentile (median 17·6 [IQR 15·0–18·3] pmol/L), and more than 5% and 10% for men with FT4 >75th (16·7 [14·0–17·4] pmol/L) and >90th percentile (18·4 [16·0–19·1] pmol/L) respectively (figure 5). There were no differences in the association of thyroid function and outcomes of interest between different races, although we only had a few studies that included non-White participants (appendix p 22). No substantial differences in the associations were identified across different iodine status (appendix p 23).

Nonlinear associations were identified for TSH, with low concentrations of TSH (below the median concentration) associated with a higher risk of the composite outcome, all-cause mortality, and CVD mortality. A trend of a somewhat higher risk of CVD mortality and all-cause mortality was implied for high concentrations of TSH. The 95% CI for the association between low TSH concentrations and CVD included one (appendix p 24). However, additional adjustment for other cardiovascular risk factors in the second model attenuated the association between high concentrations of TSH and CVD mortality (appendix p 25). Overall, TSH between the 60th (median 1·90 [IQR 1·68–2·25] mIU/L) and 80th percentiles (2·90 [2·41–3·32] mIU/L) was associated with the lowest risk of CVD and mortality.

Two-step meta-analyses showed that the 0th to 20th percentiles of TSH was associated with a higher risk of composite outcome (age- and sex-adjusted HR 1·07 [95% CI 1·02–1·12]), mortality (1·09 [1·05–1·14]), and CVD mortality (1·07 [0·99–1·16]) compared to the 60th to 80th percentiles. The association of high concentrations of TSH with all-cause mortality and CVD mortality was not supported by two-step meta-analyses (figure 3b). The effect sizes remained similar after additional adjustment with the second model (appendix p 26). I^2 values ranged from 0% to 50% with no relevant publication bias identified by funnel plots or Egger's tests (appendix pp 42–45).

There was no significant interaction between TSH and age in the association with any of the outcomes (p for interaction 0·77, 0·55, 0·25, 0·26, respectively) (appendix p 27). Interaction between TSH and sex was identified on the association with all-cause mortality and CVD mortality (p for interaction=0·073, 0·057), with a U-shaped association indicated for men (appendix p 28). There was no significant interaction between TSH and race (appendix p 29). No substantial differences in the associations were identified across different iodine status (appendix p 30).

Restricting the analyses to euthyroid participants either defined by the reference intervals used by each cohort according to the assay or the 2·5th-97·5th percentile defined per cohort showed similar results to our main analyses (appendix p 31). Excluding thyroid medication users and excluding participant with positive TPOAb did not meaningfully change the risk estimates. Using repeated measurements of thyroid function test, log-transformed TSH and

FT4 or standardized TSH and FT4 and other sensitivity analyses, did not reveal different results (appendix pp 32–37).

Discussion

In this IPD meta-analysis, there was a consistent J-shaped association of FT4 with an increased risk of composite outcome and secondary outcomes, independent of traditional cardiovascular risk factors. Low concentrations of TSH were associated with an increased risk of composite outcome. FT4 between the 20th and 40th percentiles (median 13·5–14·8 pmol/L) and TSH between the 60th to 80th percentiles (1·90–2·90 mIU/L) were associated with the lowest risk of CVD and mortality. In individuals aged over 70 years, the ten-year risk of the composite outcome increased over 5% in women with FT4 >85th percentile (median 17·6 pmol/L), and in men with FT4 >75th (16·7 pmol/L) and 90th percentile (18·4 pmol/L), the risk increased by more than 5% and 10% respectively.

In contrast to TSH, the association of FT4 with CVD and mortality was consistent and pronounced. This discrepancy in the association of TSH or FT4 on CVD and mortality has been demonstrated in previous studies, where FT4 showed evident associations with atrial fibrillation, sudden cardiac death, atherosclerotic events, and all-cause mortality, without corresponding findings for TSH.[2,13,14,33,50] A recent meta-analysis on associations of thyroid function with various clinical parameters also indicated that compared to TSH, FT4 had stronger associations with clinical outcomes, including mortality, CVD, and dementia.[12] Nevertheless, these findings have not yet led to a change on the current paradigm of diagnosis, prognosis or treatment of thyroid disorders. TSH represents the effect of thyroid hormone on the pituitary,[51] while FT4 is converted to bioactive hormone, triiodothyronine (T3), which has direct actions on the end-organs. In the cardiomyocyte, T3 binds to thyroid hormone receptor, regulating genes expression and influences the myocardial contractility. T3 also modulates the ion channels and alters cardiac chronotropy through thyroid hormone receptor independent effects.[52] TSH is considered as the most sensitive biomarker for thyroid disease due to the complex, non-linear relationship between TSH and FT4,[53] but within the general population, as our study and other studies imply,[12] the circulating concentrations of the actual hormones may be more relevant to other clinical consequences.

In concordance with the associations of FT4, low concentrations of TSH were associated with a higher risk of the composite outcome. However, this was mainly driven by the association with all-cause mortality and CVD mortality. Our finding of higher mortality risk with lower TSH is in line with a previous IPD meta-analysis of Collet et al, that indicated an increased risk of all-cause mortality and CHD mortality among participants with subclinical hyperthyroidism.[54] Our study implied that high concentrations of TSH were associated with a somewhat increased risk of all-cause and CVD mortality, but this was not further validated by two-step meta-analyses or adjustment with other cardiovascular risk factors (for CVD mortality). Moreover, no statistically significant association of TSH with CVD events was identified. This is partially in line with a previous IPD analysis, which demonstrated no overall significant association of subclinical hypothyroidism with CHD events, CHD mortality, and all-cause mortality, but a higher risk of CHD events when TSH >10 mIU/L and a higher risk of CHD mortality when TSH >7 mIU/L.[9] There could be

several explanations for this discrepancy. First, we conducted a different approach to analyse the association continuously across the full range of thyroid function assuming a continuum of risk, instead of categorization of TSH. Of note, TSH >7 mIU/L correspond to the 97th to 100th percentiles among our study population, which represents a group of individuals with relatively extreme conditions, while our study focused more on risk estimates among the general population. Therefore, the results from those two different approaches are not directly comparable. Second, our study included a broader definition of CVD and CVD mortality while the previous study only included CHD events and CHD mortality.[9] Third, our study included more cohorts and longer follow-up time for the cohorts that do overlap between the two studies. This is relevant as temporal changes have occurred that may have resulted in alterations in the effect of high TSH on CVD risk, including changes in iodine status, aging populations and increased efforts for cardiovascular risk management. The latter is of importance as cardiovascular risk management targets dyslipidemia, which in turn is thought to be one of the mechanisms though which hypothyroidism can cause CVD.[55]

We demonstrated that the association between FT4 and the risk of CVD and mortality differed by age and sex. More prominent associations, lower optimal healthy ranges, and higher increase of absolute risk across the range of FT4 were indicated for individuals older than 70 years. There could be several explanations but might suggest that progressive decline in cardiac reserve and reduced ability of cardioprotection during aging may render elderly individuals more vulnerable to higher thyroid hormone concentrations leading to a higher susceptibility to CVD.[56] This aligns with guidelines for (subclinical) hypothyroidism that recommend more conservative strategies and low levothyroxine starting dose for the elderly.[7,8] Compared to men, women had lower optimal healthy ranges of FT4, this may partially be explained by the lower FT4 concentrations among women, as well as the difference in set-points.[57] Because of the high background risk of CVD and mortality among men and older participants, FT4 had a greater impact on the absolute risk estimates of older men, with over 10% increased ten-year risk of composite outcome. These findings suggest age- and sex-specific strategies for thyroid disease could be necessary.

Optimal healthy ranges are not synonymous to but could be seen as a step towards improving the definition of reference ranges and hence aiding clinical decision making. Before going forward, however, there are still several challenges. Besides the need for RCTs to inform the clinical decision limits, first, it is yet to be decided whether clinical decision limits should be established based on increase in relative risk or absolute risk estimates. Despite the ongoing debate on which risk estimates should be used,[58] absolute risk estimates are held to reflect the absolute benefit with reduction of the risk and has been increasingly used in CVD management in general.[59] Second, with evidence of continuous risk (i.e., no clear thresholds), it is difficult to decide what magnitude of increased risk is acceptable to establish thresholds. Our study identified an over 5% increased ten-year risk of the composite outcome within the reference interval of FT4, which is comparable to the increase of CVD risk across the range of cholesterol in individuals above 70 years.[60] Besides, there are more thyroid function related challenges. For example, we have studied the optimal healthy ranges in the context of CVD. However, thyroid hormones are pleiotropic and variations of thyroid function are associated with multiple relevant clinical outcomes, including bone,[61] cancer,[62] and non-alcoholic fatty liver disease.[63] Which outcomes should

be included in order to define clinical decision limits are still up for debate. Furthermore, in our study, we describe age- and sex-specific optimal healthy ranges for TSH and FT4 in relation to CVD and mortality. Whether age- and sex-specific thresholds should be applied needs to be addressed, with additional evidence on the risk differences by age and sex with other thyroid-relevant outcomes needed. Nevertheless, our study provides a feasible approach, paving the way for future studies. This collective information can be used to inform future RCTs to provide evidence for more tailored clinical decision limits.

Levothyroxine (LT4) has become the second most common medication prescribed in the United States as well as in England.[64,65] Part of the rise in usage can be attributed to a declining treatment threshold in TSH.[66] Around 30% of individuals with thyroid function within the reference interval and 40% with mild to moderate subclinical hypothyroidism were prescribed with levothyroxine in 2018.[16] Due to no clear benefit and uncertainty on potential harms, a new published guideline based on evidence from RCTs recommends against thyroid hormone therapy for subclinical hypothyroidism unless TSH >20 mIU/L.[67] Our findings argue in favour of "low euthyroid status", implicating the potential risk of CVD and mortality that could accompany the LT4 therapy, especially for elderly individuals. This may further raise the concerns about overtreatment of LT4 among the elderly. Although we found no differences in our results when excluding levothyroxine users, we did not conduct subgroup analysis on participants with levothyroxine, due to insufficient sample size. Among athyreotic patients, higher FT4 might be required to achieve appropriate levels of triiodothyronine.[68] Therefore, whether our results are also applicable to all patients with thyroid hormone therapy would need to be addressed in studies specifically designed for those patients.

Our study is strengthened by using IPD to avoid biases from aggregate data and to standardize the definition of outcomes and variables used.[69] We used a composite outcome to incorporate the pleiotropic effect of thyroid hormone, although alternative approaches provided no substantial changes in estimates. We performed one-step IPD meta-analyses as our main analyses, allowing the exploration of nonlinear associations and the optimal healthy ranges. We converted TSH and FT4 into percentiles to harmonize the data from different cohorts and increase the generalizability. The results were robust for log-transformation and standardization of TSH and FT4. We used repeated measurements of thyroid function to further validate the results obtained from a single measurement. This study also has several limitations. First, the majority of included participants were White from Europe and the USA, and our results may therefore not be generalizable to other countries and non-White individuals. Second, due to power issues amongst others, we were not able to investigate the association in individuals taking thyroxine or those with a history of CVD. Studies that are specifically designed for these subgroups are needed. Third, we identified additional cohorts with the updated systematic search through October 2020 that we were not able to include in our IPD due to the considerable time needed to acquire data.[70] Nevertheless, the number of potential participants in the additional six cohorts identified was fairly limited (n=15 196) had we been able to include all. Fourth, given the observational study design, we cannot rule out the unmeasured confounding and residual confounding due to measurement error and time-varying confounding. Moreover, HRs may be limited by the built-in bias.[71] Finally, T3 was not included in this study due

to unavailability in most cohorts, therefore the conversion of T4 to T3 remains unexplored. Further studies are warranted to explore the potential additional merit of T3 measurement in the association with CVD.

In summary, our IPD meta-analysis of 134 346 participants from 26 cohorts indicated a J-shaped association of FT4 with CVD and mortality. Lower TSH was associated with an increased risk of all-cause and CVD mortality. FT4 between the 20th and 40th percentiles (median 13·5–14·8 pmol/L) and TSH between the 60th and 80th percentiles (median 1·90– 2·90 mIU/L) were identified to be the optimal healthy ranges defined by the risk of CVD and mortality. Beyond the optimal healthy ranges, more than 5% increase of ten-year risk of the composite outcome was implied for women with FT4 >85th percentile (median 17·6 pmol/L), and over 5% and 10% increase for men with FT4 >75th (16·7 pmol/L) and 90th percentile (18·4 pmol/L) respectively. These thresholds are lower than the currently applied thresholds for diagnosis and treatment of subclinical thyroid dysfunction. This risk-based analysis could be a step towards refining the reference ranges of thyroid function test and facilitate identification of individuals with a higher risk of thyroid-related outcomes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Reference

1. Ozarda Y, Sikaris K, Streichert T, Macri J, intervals ICoR, Decision L. Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits. Crit Rev Clin Lab Sci 2018; 55(6): 420–31. [PubMed: 30047297]

2. Baumgartner C, da Costa BR, Collet TH, et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation. Circulation 2017; 136(22): 2100–16. [PubMed: 29061566]

3. Chaker L, Baumgartner C, den Elzen WP, et al. Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis. J Clin Endocrinol Metab 2016; 101(11): 4270–82. [PubMed: 27603906]

4. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab 2015; 100(3): 1088–96. [PubMed: 25514105]

5. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341(6): 427–34. [PubMed: 10432328]

6. Scott MG, Neil JS, Alison LB, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25): e1082–e143. [PubMed: 30586774]

7. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22(12): 1200–35. [PubMed: 22954017]

8. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J 2013; 2(4): 215–28. [PubMed: 24783053]

9. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. Jama 2010; 304(12): 1365–74. [PubMed: 20858880]

10. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126(9): 1040–9. [PubMed: 22821943]

11. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291(2): 228–38. [PubMed: 14722150]

12. Fitzgerald SP, Bean NG, Falhammar H, Tuke J. Clinical Parameters Are More Likely to Be Associated with Thyroid Hormone Levels than with Thyrotropin Levels: A Systematic Review and Meta-Analysis. Thyroid 2020; 30(12): 1695–709. [PubMed: 32349628]

13. Groothof D, Flores-Guerrero JL, Nolte IM, et al. Thyroid function and risk of all-cause and cardiovascular mortality: a prospective population-based cohort study. Endocrine 2021; 71(2): 385–96. [PubMed: 32632723]

14. Yeap BB, Alfonso H, Hankey GJ, et al. Higher free thyroxine levels are associated with all-cause mortality in euthyroid older men: the Health In Men Study. Eur J Endocrinol 2013; 169(4): 401–8. [PubMed: 23853210]

15. Chaker L, Korevaar TIM, Rizopoulos D, et al. Defining Optimal Health Range for Thyroid Function Based on the Risk of Cardiovascular Disease. J Clin Endocrinol Metab 2017; 102(8): 2853–61. [PubMed: 28520952]

16. Brito JP, Ross JS, El Kawkgi OM, et al. Levothyroxine Use in the United States, 2008–2018. JAMA Intern Med 2021; 181(10): 1402–5. [PubMed: 34152370]

17. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed October 15 2022).

18. de Jong VMT, Moons KGM, Riley RD, et al. Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example. Res Synth Methods 2020; 11(2): 148–68. [PubMed: 31759339]

19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177–88. [PubMed: 3802833]

20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539–58. [PubMed: 12111919]

21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629–34. [PubMed: 9310563]

22. Jolani S, Debray TP, Koffijberg H, van Buuren S, Moons KG. Imputation of systematically missing predictors in an individual participant data meta-analysis: a generalized approach using MICE. Stat Med 2015; 34(11): 1841–63. [PubMed: 25663182]

23. Vincent A, Ian RW, Shahab J, et al. Multiple Imputation for Multilevel Data with Continuous and Binary Variables. Statistical Science 2018; 33(2): 160–83.

24. Peeters RP. Subclinical Hypothyroidism. N Engl J Med 2017; 376(26): 2556–65. [PubMed: 28657873]

25. The Iodine Global Network. Global scorecard of iodine nutrition in 2015–2020 in the general population based on school-age children (SAC). https://www.ign.org/cm_data/ (accessed 9th January 2023).

26. Iacoviello M, Guida P, Guastamacchia E, et al. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des 2008; 14(26): 2686–92. [PubMed: 19006851]

27. Ceresini G, Marina M, Lauretani F, et al. Relationship Between Circulating Thyroid-Stimulating Hormone, Free Thyroxine, and Free Triiodothyronine Concentrations and 9-Year Mortality in Euthyroid Elderly Adults. J Am Geriatr Soc 2016; 64(3): 553–60. [PubMed: 27000328]

28. Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 2007; 167(14): 1526–32. [PubMed: 17646607]

29. Vaes B, Pasquet A, Wallemacq P, et al. The BELFRAIL (BFC80+) study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr 2010; 10: 39. [PubMed: 20565795]

30. Meuwese CL, Gussekloo J, de Craen AJ, Dekker FW, den Elzen WP. Thyroid status and renal function in older persons in the general population. J Clin Endocrinol Metab 2014; 99(8): 2689–96. [PubMed: 24735423]

31. van de Ven AC, Netea-Maier RT, de Vegt F, et al. Associations between thyroid function and mortality: the influence of age. Eur J Endocrinol 2014; 171(2): 183–91. [PubMed: 24801590]

32. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97(3): 852–61. [PubMed: 22238391]

33. Bano A, Chaker L, Mattace-Raso FUS, et al. Thyroid Function and the Risk of Atherosclerotic Cardiovascular Morbidity and Mortality: The Rotterdam Study. Circ Res 2017; 121(12): 1392–400. [PubMed: 29089349]

34. Ittermann T, Haring R, Sauer S, et al. Decreased serum TSH levels are not associated with mortality in the adult northeast German population. Eur J Endocrinol 2010; 162(3): 579–85. [PubMed: 20007334]

35. Schmermund A, Möhlenkamp S, Stang A, et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 2002; 144(2): 212–8. [PubMed: 12177636]

36. Boekholdt SM, Titan SM, Wiersinga WM, et al. Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. Clin Endocrinol (Oxf) 2010; 72(3): 404–10. [PubMed: 19486022]

37. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358(9285): 861–5. [PubMed: 11567699]

38. Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab 2010; 95(4): 1734–40. [PubMed: 20150579]

39. Saely CH, Leiherer A, Muendlein A, et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis 2016; 244: 38–43. [PubMed: 26590865]

40. Aquino EM, Barreto SM, Bensenor IM, et al. Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): objectives and design. Am J Epidemiol 2012; 175(4): 315–24. [PubMed: 22234482]

41. Sgarbi JA, Matsumura LK, Kasamatsu TS, Ferreira SR, Maciel RM. Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese-Brazilian thyroid study. Eur J Endocrinol 2010; 162(3): 569–77. [PubMed: 19966035]

42. Waring AC, Rodondi N, Harrison S, et al. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. Clin Endocrinol (Oxf) 2012; 76(6): 911–8. [PubMed: 22187968]

43. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials 2005; 26(5): 569–85. [PubMed: 16084776]

44. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. Jama 2006; 295(9): 1033–41. [PubMed: 16507804]

45. Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of Subclinical Hypothyroidism and Cardiovascular Disease With Mortality. JAMA Netw Open 2020; 3(2): e1920745. [PubMed: 32031647]

46. Inoue K, Tsujimoto T, Saito J, Sugiyama T. Association Between Serum Thyrotropin Levels and Mortality Among Euthyroid Adults in the United States. Thyroid 2016; 26(10): 1457–65. [PubMed: 27539006]

47. Tohidi M, Derakhshan A, Akbarpour S, et al. Thyroid Dysfunction States and Incident Cardiovascular Events: The Tehran Thyroid Study. Horm Metab Res 2018; 50(1): 37–43. [PubMed: 29132170]

48. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89(7): 3365–70. [PubMed: 15240616]

49. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165(21): 2467–72. [PubMed: 16314542]

50. Chaker L, van den Berg ME, Niemeijer MN, et al. Thyroid Function and Sudden Cardiac Death: A Prospective Population-Based Cohort Study. Circulation 2016; 134(10): 713–22. [PubMed: 27601558]

51. Larsen PR. Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med 1982; 306(1): 23–32. [PubMed: 7031472]

52. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14(1): 39–55. [PubMed: 27811932]

53. Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. The relationship between TSH and free T_4 in a large population is complex and nonlinear and differs by age and sex. J Clin Endocrinol Metab 2013; 98(7): 2936–43. [PubMed: 23671314]

54. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10): 799–809. [PubMed: 22529182]

55. Su X, Peng H, Chen X, Wu X, Wang B. Hyperlipidemia and hypothyroidism. Clin Chim Acta 2022; 527: 61–70. [PubMed: 35038435]

56. Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin 2012; 8(1): 143–64. [PubMed: 22108734]

57. Chaker L, Korevaar TI, Medici M, et al. Thyroid Function Characteristics and Determinants: The Rotterdam Study. Thyroid 2016; 26(9): 1195–204. [PubMed: 27484151]

58. Chapelle N, Martel M, Barkun AN, Bardou M. Relative risk rather than absolute risk reduction should be preferred to sensitise the public to preventive actions. Gut 2022; 71(6): 1045–6. [PubMed: 33811040]

59. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000; 320(7236): 659–61. [PubMed: 10710556]

60. group SOw, collaboration ESCCr. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal 2021; 42(25): 2455–67. [PubMed: 34120185]

61. Aubert CE, Floriani C, Bauer DC, et al. Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts. J Clin Endocrinol Metab 2017; 102(8): 2719–28. [PubMed: 28482002]

62. Khan SR, Chaker L, Ruiter R, et al. Thyroid Function and Cancer Risk: The Rotterdam Study. J Clin Endocrinol Metab 2016; 101(12): 5030–6. [PubMed: 27648963]

63. Bano A, Chaker L, Plompen EP, et al. Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study. J Clin Endocrinol Metab 2016; 101(8): 3204–11. [PubMed: 27270473]

64. Kane SP. Levothyroxine, ClinCalc DrugStats Database, Version 2022.08. August 24, 2022. ClinCalc: https://clincalc.com/DrugStats/Drugs/Levothyroxine. (accessed January 9, 2023.

65. Prescription Cost Analysis - England, 2018 [PAS] March 28, 2019. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018 (accessed January 9 2023).

66. Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 2014; 174(1): 32–9. [PubMed: 24100714]

67. Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ 2019; 365: l2006. [PubMed: 31088853]

68. Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 2008; 299(7): 769–77. [PubMed: 18285588]

69. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221. [PubMed: 20139215]

70. Veroniki AA, Ashoor HM, Le SPC, et al. Retrieval of individual patient data depended on study characteristics: a randomized controlled trial. J Clin Epidemiol 2019; 113: 176–88. [PubMed: 31153977]

71. Hernán MA. The hazards of hazard ratios. Epidemiology 2010; 21(1): 13–5. [PubMed: 20010207]

Research in context

Evidence before this study

Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are statistically defined by the 2·5th-97·5th percentiles, without accounting for potential risk of clinical outcomes. Therefore, current reference intervals may fail to identify individuals with a higher risk of disease who could potentially benefit from intervention. We identified eligible prospective cohorts through the Thyroid Studies Collaboration, supplemented with a systematic search via Embase, MEDLINE, Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from January 2011 to October 2022. We included cohorts that collected TSH and/or FT4, cardiovascular outcomes and/or mortality for adults.

Added value of this study

With individual participant data from 134 346 participants, our study showed a J-shaped association of FT4 with CVD events, all-cause mortality, and CVD mortality, as a composite outcome or individual outcomes, with the 20th-40th percentiles (median 13·5–14·8 pmol/L) of FT4 conveying the lowest risk. Among individuals 70 years, the ten-year absolute risk estimate increased more than 5% for women with FT4 >85th percentile (median 17·6 pmol/L), and over 5% and 10% for men with FT4 >75th (16·7 pmol/L) and >90th percentile (18·4 pmol/L) respectively. Low concentrations of TSH were associated with a higher risk of all-cause mortality and CVD mortality, with the 60th to 80th percentiles (median 1·90–2·90 mIU/L) associated with the lowest risk.

Implications of all the available evidence

Our study indicated a J-shaped association of FT4 with CVD and mortality. Low concentrations of TSH were associated with a higher risk of all-cause mortality and CVD mortality. Based on the risk estimates, the optimal healthy ranges of thyroid function may lie within 20th–40th percentiles of FT4 and the 60th-80th percentiles of TSH. In men and women aged above 70 years, FT4 >85th percentile concurred with an over 5% increase of ten-year composite risk of CVD and mortality. This threshold is lower than the currently applied threshold for diagnosis and treatment of subclinical thyroid dysfunction. Further studies are warranted specifically in patients using thyroid hormone supplementation.

Figure 1:
PRISMA flow chart of included cohorts

Figure 2:
Association of FT4 percentiles with composite outcome, all-cause mortality, CVD mortality, and CVD events. Hazard ratios were plotted against FT4 percentiles taking the FT4 percentile with the lowest hazard ratio as the reference. Hazard ratios were adjusted for age and sex. The shaded band represents the 95% confidence interval. FT4=free thyroxine. CVD=cardiovascular disease. P denotes the p value for the association of exposure with the outcome. No. of events/No. of participants: composite outcome, 14904/51081 (29.2%);

all-cause mortality, 21873/94295 (23.2%); CVD mortality, 6866/82926 (8.3%); CVD events, 9990/51081 (19.6%).

a. FT4 percentiles	No. events/total (%)	HR (95% CI)		b. TSH percentiles	No. events/total (%)	HR (95% CI)
Composite outcome				**Composite outcome**		
0th–20th	2912/10343 (28.2)	1.04 (0.98–1.11)		0th–20th	3876/11794 (32.9)	1.07 (1.02–1.12)
20th–40th	2784/10238 (27.2)	1 [Reference]		20th–40th	3626/11843 (30.6)	1.01 (0.96–1.05)
40th–60th	2910/10267 (28.3)	1.02 (0.97–1.08)		40th–60th	3597/12081 (29.8)	1.03 (0.99–1.08)
60th–80th	3010/10229 (29.4)	1.07 (1.01–1.12)		60th–80th	3569/12271 (29.1)	1 [Reference]
80th–100th	3288/10004 (32.9)	1.20 (1.11–1.31)		80th–100th	3505/11918 (29.4)	0.99 (0.93–1.05)
Overall mortality				**Overall mortality**		
0th–20th	4067/20112 (20.2)	1.04 (0.99–1.09)		0th–20th	6769/26644 (25.4)	1.09 (1.05–1.14)
20th–40th	4202/21962 (19.1)	1 [Reference]		20th–40th	6179/26806 (23.1)	0.99 (0.95–1.03)
40th–60th	4252/20483 (20.8)	1.08 (1.02–1.14)		40th–60th	6267/26711 (23.5)	1.03 (0.99–1.07)
60th–80th	4677/20776 (22.5)	1.15 (1.07–1.24)		60th–80th	6398/27068 (23.6)	1 [Reference]
80th–100th	5495/20084 (27.4)	1.34 (1.20–1.49)		80th–100th	7330/27115 (27.0)	1.03 (0.97–1.09)
CVD mortality				**CVD mortality**		
0th–20th	1241/17821 (7.0)	1.09 (0.996–1.20)		0th–20th	2031/24336 (8.3)	1.07 (0.99–1.16)
20th–40th	1228/19749 (6.2)	1 [Reference]		20th–40th	1882/24536 (7.7)	0.98 (0.92–1.05)
40th–60th	1263/18132 (7.0)	1.13 (1.02–1.26)		40th–60th	1869/24436 (7.6)	1.01 (0.95–1.08)
60th–80th	1513/18579 (8.1)	1.35 (1.18–1.55)		60th–80th	1982/24803 (8.0)	1 [Reference]
80th–100th	1759/17757 (9.9)	1.57 (1.31–1.89)		80th–100th	2312/24828 (9.3)	1.01 (0.91–1.12)
CVD events				**CVD events**		
0th–20th	1907/10343 (18.4)	1.02 (0.95–1.10)		0th–20th	2557/11794 (21.7)	1.02 (0.97–1.08)
20th–40th	1876/10238 (18.3)	1 [Reference]		20th–40th	2454/11843 (20.7)	0.99 (0.93–1.06)
40th–60th	1937/10267 (18.9)	1.01 (0.95–1.08)		40th–60th	2410/12081 (19.9)	1.00 (0.95–1.06)
60th–80th	2040/10229 (19.9)	1.08 (1.01–1.15)		60th–80th	2455/12271 (20.0)	1 [Reference]
80th–100th	2230/10004 (22.3)	1.22 (1.11–1.33)		80th–100th	2336/11918 (19.6)	0.97 (0.90–1.04)

Figure 3:

Association of quintiles of TSH and FT4 with the composite outcome, all-cause mortality, CVD mortality, and CVD events. Hazard ratios were adjusted for age and sex. TSH=thyroid stimulating hormone. FT4=free thyroxine. CVD=cardiovascular disease.

Figure 4:
Association between FT4 percentiles and composite outcome stratified by age categories. Hazard ratios were plotted against FT4 percentiles taking the FT4 percentile with the lowest hazard ratio as reference. Hazard ratios were adjusted for age and sex. The shaded band represents the 95% confidence interval. FT4=free thyroxine. P denotes the p value for the association of exposure with the outcome. No. of events/No. of participants: age 18–49, 889/14659 (6.1%); age 50–69, 5374/22176 (24.2%); age 70–79, 6391/11007 (58.1%); age ≥ 80, 2250/3239 (69.5%).

Figure5:
Absolute ten-year risk of the composite outcome by FT4 percentiles stratified by age and sex. FT4=free thyroxine. No. of events/No. of participants: women aged <70 years 2659/20401 (13.0%), men aged <70 years 3604/16434 (21.9%), women aged 70 years 3720/5828 (63.8%), men aged 70 years 4921/8418 (58.5%).

Table:

Characteristics of included studies and their participants

Study, year (Reference)	n	Country	Median age (range)[*]	Women	Thyroid medication at baseline[†]	Thyroid medication during follow-up[‡]	TSH, mIU/L, median (IQR)	FT4, pmol/L, mean (SD)	Follow-up time, median (IQR)	Person-Years
Bari Study, 2006–2018[26]	338	Italy	67 (22–93)	78 (23·1%)	23 (6·8%)	63 (18·6%)	1·75 (1·14–3·00)	16·4 (3·2)	7·3 (2·6–11·3)	2326
InCHIANTI Study, 1998–2010[27]	1213	Italy	71 (21–102)	684 (56·4%)	33 (2·7%)	56 (4·6%)	1·32 (0·84–2·00)	18·6 (4·6)	9·1 (7·6–9·3)	9695
Pisa Cohort[§], 1992–2016[28]	9067	Italy	68 (18–98)	3165 (34·9%)	541 (6·0%)	NA	1·60 (0·93–2·60)	12·3 (4·9)	6·3 (3·8–9·3)	58153
Belfrail Study, 2008–2014[29]	545	Belgium	84 (80–102)	343 (62·9%)	52 (9·5%)	25 (4·6%)	1·19 (0·74–1·76)	11·9 (2·6)	4·9 (3·1–5·2)	2233
Leiden 85-plus Study, 1997–2009[30]	558	the Netherlands	85 (NA)	370 (66·3%)	21 (3·8%)	39 (7·0%)	1·82 (1·16–2·90)	14·6 (2·7)	5·4 (2·7–8·6)	3204
NBS, 2000–2015[31]	6677	the Netherlands	57 (18–98)	3575 (53·5%)	119 (1·8%)	193 (2·9%)	1·37 (0·92–2·00)	13·6 (2·6)	13·6 (13·3–13·9)	83911
PREVEND Study (NC1), 1997–2016[13]	2703	the Netherlands	46 (28–75)	1389 (51·4%)	NA	72 (2·7%)	1·36 (0·95–1·93)	12·8 (2·4)	18·9 (13·5–19·1)	42255
PREVEND Study (NC2), 2001–2016[13]	4554	the Netherlands	53 (32–80)	2253 (49·2%)	90 (2·0%)	140 (3·1%)	1·59 (1·1–12·33)	15·6 (2·4)	13·9 (11·3–14·3)	56337
PROSPER trial, 1997–2012[32]	5796	Scotland, Ireland, and the Netherlands	75 (69–83)	2996 (51·7%)	259 (4·5%)	349 (6·0%)	1·88 (1·2–12·76)	NA	3·3 (3·0–3·5)	18637
Rotterdam Study I-III, 1997–2015[33]	9681	the Netherlands	63 (46–106)	5499 (56·8%)	308 (3·2%)	530 (5·5%)	1·90 (1·28–2·77)	15·7 (2·3)	8·8 (7·0–14·4)	100255
SHIP-START Study, 1997–2019[34]	3849	Germany	49 (20–81)	1970 (51·2%)	247 (6·4%)	572 (14·9%)	0·81 (0·53–1·19)	14·4 (2·3)	19·6 (18·5–20·4)	68339
Heinz Nixdorf Recall Study, 2000–2018[35]	4316	Germany	60 (45–76)	2171 (50·3%)	NA	NA	1·26 (0·83–1·84)	17·0 (3·1)	13·9 (10·4–15·5)	55034
EPIC-Norfolk Study, 1995–2010[36]	13393	UK	59 (40–78)	7340 (54·8%)	490 (3·7%)	NA	1·70 (1·20–2·50)	12·5 (3·9)	13·4 (12·6–14·3)	171664
Birmingha m Study, 1988–1999[37]	1191	UK	68 (60–94)	681 (57·2%)	0 (NA)	53 (4·5%)	1·60 (1·00–2·50)	NA	10·2 (5·5–10·6)	9626
Whickham Survey[¶], 1972–1992[38]	2691	UK	46 (18–93)	1433 (53·3%)	110 (4·1%)	90 (3·3%)	2·10 (1·00–3·20)	8·4 (2·0)	19·0 (15·0–20·0)	43832
VIVIT Cohort, 1999–2018[39]	1717	Austria	65 (27–88)	585 (34·1%)	NA	NA	1·58 (0·97–2·35)	NA	11·0 (7·6–12·2)	18152

Study, year (Reference)	n	Country	Median age (range)[*]	Women	Thyroid medication at baseline[†]	Thyroid medication during follow-up[‡]	TSH, mIU/L, median (IQR)	FT4, pmol/L, mean (SD)	Follow-up time, median (IQR)	Person-Years
ELSA-Brasil Study, 2008–2018[40]	13625	Brazil	51 (35–74)	7397 (54·3%)	1038 (7·6%)	1190 (8·7%)	2·01 (1·39–2·92)	15·5 (2·6)	9·2 (8·7–9·5)	122800
Japanese-Brazilian Thyroid Study, 1999–2007[41]	1110	Brazil	57 (30–92)	591 (53·2%)	0 (NA)	NA	1·40 (0·82–2·46)	14·2 (6·3)	7·3 (7·0–7·5)	7789
Health, ABC Study, 1997–2012[42]	2799	USA	74 (69–81)	1434 (51·2%)	278 (9·9%)	469 (16·8%)	2·14 (1·37–3·23)	NA	11·9 (7·5–12·3)	28085
MrOS Study, 2000–2021[43]	1602	USA	73 (65–99)	0 (NA)	123 (7·7%)	213 (13·3%)	2·07 (1·38–3·10)	12·7 (2·1)	13·8 (8·3–19·0)	20828
Cardiovascular Health Study, 1994–2017[44]	4000	USA	74 (64–98)	2362 (59·1%)	403 (10·1%)	764 (19·1%)	2·13 (1·37–3·33)	15·7 (3·1)	11·8 (6·7–17·8)	48939
NHANES, (1999, 2001, 2007, 2009, 2011)2015[45]	12174	USA	48 (18–85)	6087 (50·9%)	733 (6·2%)	NA	1·54 (1·04–2·28)	10·4 (2·1)	7·7 (5·6–8·8)	99616
NHANES III, 1988–2015[46]	15945	USA	43 (18–90)	8478 (52·2%)	458 (3·3%)	NA	1·50 (1·00–2·24)	NA	22·4 (15·7–24·6)	311471
TTS, 1997-2018[47]	5763	Iran	38 (20–90)	3392 (58·9%)	177 (3·1%)	358 (6·2%)	1·61 (0·96–2·66)	15·9 (5·2)	18·1 (15·5–18·5)	97911
Nagasaki Adult Health Study, 1984–1998[48]	2830	Japan	57 (38–92)	1723 (60·9%)	46 (1·6%)	7 (0·2%)	2·90 (2·10–3·90)	18·4 (5·9)	13·0 (12·3–13·6)	34333
Health in Men Study, 2001–2012[14]	4106	Australia	76 (70–89)	0 (NA)	139 (3·4%)	NA	1·99 (1·40–2·85)	16·1 (2·5)	8·7 (7·4–9·6)	32910
Busselton Health Study, 1981–2001[49]	2103	Australia	51 (18–90)	1042 (49·5%)	28 (1·3%)	47 (2·2%)	1·45 (0·98–2·09)	16·3 (4·2)	20·0 (19·3–20·0)	37219
Overall	**134346**	**26 cohorts**	**59 (18–106)**	**67023 (49·9%)**	**5722 (4·6%)**	**5230 (7·2%)**	**1·66 (1·07–2·56)**	**14·3 (4·0)**	**11·5 (7·7–14·9)**	**1585554**

TSH=Thyroid stimulating hormone; FT4=free thyroxine; T4=Thyroxine. InCHIANTI=Invecchiare in Chianti; NBS=Nijmegen Biomedical Study; PREVEND=Prevention of Renal and Vascular Endstage Disease; PROSPER=Prospective Study of Pravastatin in the Elderly at Risk; SHIP=Study of Health in Pomerania; EPIC=European Prospective Investigation of Cancer; VIVIT cohort= a cohort from Vorarlberg Institute for Vascular Investigation and Treatment; Health ABC study=Health, Aging, and Body Composition Study; NHANES=National Health and Nutrition Examination Survey; MrOS=Osteoporotic Fractures in Men Study; TTS=Tehran Thyroid Study.

[*] Participants <18 years of age were excluded.

[†] Participants with missing information on thyroid medication at baseline: Belfrail 2, MrOS 87, NBS 138, RS 295, Whickham 2, TTS 69, ELSA-Brasil 16.

[‡] Participants with missing information on thyroid medication during follow-up: Belfrail 139, Birmingham 1026, CHS 12, MrOS 217, RS 89, Whickham 1624, TTS 2702, ELSA-Brasil 974, PREVEND 969.

[§] Excluded patients with acute coronary syndrome or severe illness.

[¶] Whickham survey performed a first-generation assay for TSH and total T4 assays instead of free T4 assays.